Catalyst Wire Dossier Catalyst Wire Dossier

ALVAC-HIV vCP205 (live recombinant Canarypox)

ALVAC-HIV vCP205
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ALVAC-HIV vCP205 (live recombinant Canarypox), covering 2021-11-04 to 2021-11-04. Get the full timeline:

Most recent: Clinical Trial Update: A Phase II Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 With or Without HIV-1 SF-2 RGP120 in HIV-1 Uninfected Adult Volunteers [Phase 2]

See pricing